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Introduction 
Tuberculosis is a chronic disease caused by Mycobacterium tuberculosis. 
The disease occurs throughout the world and remains an important cause 
of morbidity and mortality in many developing countries. Each year, it is 
estimated that 8 million new cases occur and that it causes three million 
deaths. Whereas its prevalence has declined considerably in the 
industrial world within the last 50 years, it has re-emerged among 
patients with human immunodeficiency virus. 
The use of chemotherapy has contributed generously to the rapid decline 
in tuberculosis mortality occurring in the last four decades. The use of 
chemotherapy in non-compliant patients has been successful to a much 
lesser extent. Fixed-dose combination products have been formulated to 
minimize the compliance required for the patient to adhere to the 
treatment regimen. The quality control and bioavailability of fixed dose 
combination preparations has recently been disputed. 
Three studies were performed in order to: 
Study A 
Analyse the local behaviour of tuberculosis since it became a notifiable 
disease by legislation in 1908; and study the impact of chemotherapy on 
the epidemiology of tuberculosis in Malta. 
StudyB 
Assess the compliance with prescribed treatment regimens among 
tuberculosis patients. 
StudyC 
Perform and compare the in vitro dissolution profile of a locally 
manufactured generic preparation of Rifampicin 300mg and Isoniazid 
150mg tablets to that of Rimactazid 300 tablets and to compare the rates 
of release of rifampicin from these formulations with the release of 
rifampicin from Rimactane 300 capsules. 
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Methodology 
Study A 
Epidemiology 
Descriptive epidemiology of tuberculosis in Malta was based on data 
obtained mainly from the National Tuberculosis Register, Tuberculosis 
Annual Reports, Vital Statistics, WHO and local publications. The 
advances made in the management and control of tuberculosis throughout 
the latter half of this century were reviewed. 
StudyB 
Patient Interviews 
Interviews were conducted with 11 diagnosed tuberculosis out-patients 
attending the chest clinic at S1. Luke's Hospital, either for treatment or 
as follow-up cases, during the period November-December 1991. The 
patients' histories were analysed before each interview. 
StudyC 
Dissolution Testing 
The apparatus used to dissolve the tablets/capsules complied with the 
requirements as specified in the BP 1988, Appendix XII D, Apparatus I. 
The test method for the dissolution of rifampicin and isoniazid tablets 
was a validated method obtained from 'International Dispensary 
Association' laboratory (Netherlands). The test method for the 
dissolution of rifampicin capsules was the one suggested in the USP XXII. 
Results 
Study A 
Epidemiology 
Since 1910 with the exception of two peaks in 1918 and 1942, the 
tuberculosis notification rate has declined rapidly to the present low 
level of 3.0 per 100,000 population. The tuberculosis mortality rate has 
followed the same pattern but at a lower level. Table 1 shows a dramatic 
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fall in tuberculosis mortality rate occurring in the 1950's. This coincides 
with the introduction of isoniazid and other drugs of choice in the 
treatment of tuberculosis. 
Table 1: Mortality per year per 100,000 population 
Period 
1910-1919 
1920-1929 
1930-1939 
1940-1949 
1950-1959 
1960-1969 
1970-1979 
1980-1989 
No of Deaths from 
pulmonary TB 
2,080 
1,501 
1,306 
1,506 
412 
101 
14 
8 
Rates 
/100,000 
193.0 
66.1 
51.1 
52.5 
13.1 
3.2 
0.5 
0.2 
% of previous 
rate 
34.2 
77.3 
102.7 
25.0 
24.4 
15.6 
40.0 
The infectivity rate, as determined by tuberculin sensitivity testing, in 
1987, was estimated at 2.5% as opposed to 33.12% in 1950. 
StudyB 
Patient Interviews 
Interviews showed that: 
i) 65% (n=7) were ready to communicate problems related to their 
condition to the pharmacist; 
i i) the majority of all patients had a fair knowledge on the 
disease/treatment regimen and wanted to know more; 
iiD all the patients (n=l1) claimed to be taking the medication as 
prescribed by the medical officer in charge and attended the chest 
clinic regularly; 
v) at least 36.3% (n=4) were not informed about the possible side-
effects of certain drugs. 
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StudyC 
Dissolution testing 
Table 2: Percentage content dissolved at various time intervals of the 3 
formulations subjected to dissolution testing. 
Time 
lapse 
(mins) 
Percentage content dissolved 
A B c 
Rifampicin Isoniazid Rifampicin Isoniazid Rifampicin 
15.0 
30.0 
45.0 
90.96% 
97.89% 
99.90% 
78.9% 
87.12% 
93.12% 
A = Rimactizid 300 tabs 
81.00% 
85.44% 
91.26% 
B = Rifampicin 300mg + Isoniazid 150mg tabs 
C = Rimactane 300 caps 
84.48% 
88.80% 
95.04% 
90.96% 
93.90% 
93.45% 
Table 3: Statistical analysis by student's t-test of above results 
Formulations 
A vs B (n=l1) 
(Rif am picin) 
A vsC (n=12) 
(Rifampicin) 
B vs C (n=ll) 
(Rifampicin) 
A vs B (n=l1) 
(Isoniazid) 
to = ttabulated 
t-values at various time intervals (P>0.05) 
15 min 30 min 45 min 
te = 2.262 to = 2.262 10= 2.2620 
te= 12.877 tc = 16.794 te = 5.0933 
te = 2.228 to = 2.2280 to = 2.2280 
to = 0.000 te = 5.2253 te = 4.2562 
to = 2.2620 te = 2.2620 to = 2.2620 
te = 9.5697 te =17.6300 tc = 3.2704 
to = 2.2620 to = 2.2620 to = 2.2620 
te = 4.8487 te = 1.4569 tc= 1.5557 
te = tcalculated 
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Discussion 
The incidence of tuberculosis in Malta as reflected by the notification 
rates compare more than favourably with that of other countries. The 
mortality rate can no longer be used as a yardstick in assessing the 
situation because of the great reduction in the case fatality rate. The 
estimated 2% tuberculin positivity' that prevailed during the 1990's is 
very close to the 1 % required by the World Health Organisation 
Standards. 
Hospital pharmacists can increase patient compliance when a 
prescription is collected, counselling being their major tool in the process. 
It should be recognised that obeying instructions is not the problem, 
rather understanding and being motivated to comply. 
With respect to Isoniazid, the dissolution profile of the locally 
manufactured generic compares very well to that of the more established' 
Rimactazid 300 tablets, the amount of isoniazid appearing in solution in 
the first 15 minutes being greater for the local product, this then 
decreasing to values statistically equivalent to the foreign product. 
With respect to rifampicin, the local product appears to be statistically 
less soluble than either the Rimactazid 300 tabs or the Rimactane 300 
caps at all times. These latter two products show a similar solubility at 
15 minutes but the Rimactazid is subsequently more soluble than the 
Rimactane 300. Nevertheless, in vitro dissolution testing does not offer 
any basis for substitution of in vitro for in vivo bioequivalence testing. 
Conclusion 
The results achieved with chemotherapy during the last four decades 
should not encourage complacency. Compliance with chemotherapy 
depends mainly on the competence and conscientiousness of the health 
care team. It can be absolute if the treatment is fully and carefully 
explained at the very start to the patient and his family. The use of 
antituberculous' drugs, single or combined, of demonstrated 
bioavailability and quality control, is recommended. 
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